Year in Review: Updates in Antibody-Drug Conjugates for Treating Advanced NSCLC - Episode 5
Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.